GlassScriptPhysician profile
Robert D Ross
NPI 1780671313
$518.71
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $307 · 2020: $134 · 2022: $35.45 · 2023: $21.97 · 2024: $20.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $42.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $42.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $73.71 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $62.16 | 2019 | |
| Novo Nordisk INC | $47.36 | 2019-2020 | |
| Pfizer INC. | $45.75 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $36.22 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.11 | 2020 | |
| Lilly USA, LLC | $35.08 | 2019-2023 | Olumiant, Taltz |
| Sanofi Pasteur INC. | $32.86 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $29.97 | 2019 | |
| Abbott Laboratories | $23.66 | 2022 | |
| Boston Scientific Corporation | $21.96 | 2019 | |
| Ucb, INC. | $20.79 | 2024 | Nayzilam |
| Glaxosmithkline, LLC. | $18.41 | 2019 | |
| Althera Pharmaceuticals LLC | $11.79 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $11.75 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $11.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.